Lysosomal Pathophysiology of Parkinson's Disease

Erscheinungsjahr 2025
ISBN: 978-0-443-24050-8
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm

Parkinson’s Disease is a complex disease that affects millions of patients worldwide. Lysosomal pathophysiology has become an emerging key to better understanding the progression of Parkinson’s Disease. Lysosomal Pathophysiology of Parkinson’s Disease introduces how genetic and genomic insights shape the molecular view on Parkinson’s Disease. Specifically, this book presents data on the involvement of the autophagy-lysosome pathway in pathogenic processes. This book draws a timeline of disease onset and progression by examining the impact of autophagy-lysosome function to include other mechanisms and how to link these stages using the molecular lens. In addition, chapters will compare this example in Parkinson’s disease to other neurodegenerative diseases characterized by protein pathology and synaptic alterations, such as Alzheimer’s disease and Frontotemporal Dementia.

Autoren/Hrsg.

Volta, Mattia

Beccano-Kelly, Dayne

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft

Inhaltsverzeichnis

Part 1: A molecular reappraisal of Parkinson’s disease
1. Clinical and neuropathological presentation of Parkinson’s disease
2. The genetic revolution: towards an etiology-based view
3. Neuronal processes involved in etiology
4. Non-neuronal mechanisms of disease
5. The autophagy-lysosome pathway as convergence point of pathogenesis

Part 2: Autophagy-Lysosome function in Parkinson’s pathophysiology
6. Molecular biology of the autophagy pathway
7. The functional roles of lysosomes
8. Physiology of lysosomes in the critical electrophysiological function of neurons
9. Lysosomes in Parkinson’s disease neuropathology
10. Lysosomal dysfunction in Parkinson’s disease etiology

Part 3: Therapeutic options targeting lysosome biology
11. Current therapies for PD
12. Targeting options in lysosome biology
13. Autophagy-Lysosome-based therapies in neurological disorders
14. An update on clinical trials for autophagy-lysosome therapies in Parkinson’s disease
15. Prospective targeting strategies and drug development

Part 4: Neurobiological commonalities with other neurodegenerative proteinopathies
16. The autophagy-lysosome pathway and overlaps with Alzheimer-like pathologies
17. The autophagy-lysosome pathway in other neurodegenerative diseases
18. Synaptic dysfunction in neurodegeneration
19. Towards a common pathophysiology scenario in neurodegenerative diseases?

Über Autor(innen)

Volta, Mattia
Dr. Volta is a Senior Researcher and Team Leader at Eurac Research, in Italy. He has worked in Parkinson's disease for his whole career, applying several complementary approaches in vitro and in vivo to better understand the causes of the disease and how to tackle them therapeutically. His current team has developed a strong focus on the investigation of the autophagy-lysosome pathway, assessing how it is affected by genes linked to Parkinson's and identifying novel molecular mechanisms that could underlie disease etiology. This mechanistic effort is aimed at nominating and validating novel, effective targets for neuroprotection.

Beccano-Kelly, Dayne
Dr. Beccano-Kelly is a UKRI Future Leader Fellow and expert on synaptic dysfunction in Parkinson's disease. With a degree in Biochemistry and over 17 years of neurodegenerative research experience, he has numerous publications in the field of electrophysiology, molecular mechanism in neurodegenerative conditions. His particular focus has been on Parkinson's, utilizing various models of the disease including induced pluripotent stem cells and murine models. Via assessment of late-onset disease causing mutations in critical genes (LRRK2, GBA, VPS35, DNAJC13) his target has been to recapitulate the insidious and progressive nature of Parkinson's disease in an effort to understand the pathophysiological timeline and identify ways in which to intervene with the disease process